Thursday, June 05, 2025 | 10:28 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

India's first indigenous mRNA vax Gemcovac-19 likely to be available soon

Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled

Gennova
premium

Gennova Biopharmaceuticals

Sohini Das Mumbai
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, announced that its mRNA vaccine - Gemcovac-19 - against Covid-19 received the Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI).

Gemcovac-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world.

Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled.

Apart from India, Gennova aims to provide access to low-and middle-income countries around the world to the vaccine to blunt